Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BD113vVLP
- Development stage
- Unknown
- Lead developer
- Shanghai BDgene Therapeutics
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, CRISPR-Cas9 → CRISPR Systems → Programmable Nucleases → Gene Editing → Gene Therapies, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intracameral
01
Overview
BD113vVLP is an experimental gene-editing **therapy based on CRISPR/Cas9 technology** delivered via a virus-like particle, developed for the treatment of **primary open-angle glaucoma (POAG)** in patients with MYOC gene mutations and elevated intraocular pressure. It is administered as a single intracameral (intraocular) injection and is designed to knock out or downregulate the mutated MYOC gene, with the goal of lowering intraocular pressure and mitigating disease progression. This is a first-in-human clinical study testing the safety, tolerability, and preliminary efficacy of this modality in a targeted population[1][2][3][5].
- Other names
- BD113vVLPBD-113vVLPBD 113vVLPBD113vLVPBD-113vLVPBD 113vLVPBD113 virus-like particleBD-113 virus-like particleBD 113 virus-like particle
02
Targets
MYOC (Myocilin)
Beyond the preview
Go deeper on BD113vVLP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BD113vVLP.